Fig. 9

Efficacy of iBET151 and iBET762 on 3D Matrigel PDOs expressing p60AmotL2. A, B, and C Dose‒response viability testing with CTG after 72 h of treatment with iBET151 and iBET762 on PDOs derived from Patient 1 (A), Patient 2 (B), and Patient 3 (C), respectively. The IC50 values were calculated using the dose‒response nonlinear regression model from GraphPad Prism. The percentage of viability for p60AmotL2-expressing PDOs is represented by the pink and purple lines and is compared to control PDOs (black and green lines). From top to bottom, 95% CI for Patient 1 (A): iBET151 [22.26, 67.70], [1.709, 4.370], [17.18, 93.10], [2.085, 10.35] and iBET762 [41.89, 117.7], [4.408, 15.04], [39.59, 93.17], [4.425, 16.12]; Patient 2 (B): iBET151 [10.02, 20.52], [2.937, 6.264], [7.819, 16.54], [2.203, 4.644] and iBET762 [10.50, 28.52], [3.877, 9.456], [12.02, 26.67], [5.264, 11.30]; Patient 3 (C): iBET151 [15.92, 35.67], [6.208, 14.38] and iBET762 [28.83, 46.62], [9.561, 19.03]. Data represent the mean ± SEM from three independent experiments